Li Shiyu, Zhong Shenquan
Department of Ophthalmology, The First People's Hospital of Chongqing Liangjiang New Area, Chongqing, China.
Postepy Dermatol Alergol. 2023 Apr;40(2):326-330. doi: 10.5114/ada.2023.127647. Epub 2023 May 31.
Allergic conjunctivitis is one of the most common non-traumatic extraocular inflammatory diseases.
The comparison of olopatadine with ketotifen remains elusive for the treatment of allergic conjunctivitis, and this meta-analysis aims to explore the impact of olopatadine versus ketotifen on treatment efficacy for allergic conjunctivitis.
PubMed, Embase, Web of Science, EBSCO, and Cochrane library databases were systematically searched, and we included randomized controlled trials (RCTs) assessing the effect of olopatadine versus ketotifen on efficacy in patients with allergic conjunctivitis. Seven RCTs were included in the meta-analysis.
Overall, compared with ketotifen intervention for allergic conjunctivitis, olopatadine intervention was associated with substantially lower hyperaemia (mean difference (MD) = -0.77; 95% confidence interval (CI) = -1.24 to -0.30; = 0.001), but demonstrated no significant impact on itching, tearing or papillae.
These suggested that olopatadine may be more effective to relieve the symptoms of allergic conjunctivitis than ketotifen.
过敏性结膜炎是最常见的非创伤性眼外炎症性疾病之一。
在过敏性结膜炎的治疗中,奥洛他定与酮替芬的比较尚无定论,本荟萃分析旨在探讨奥洛他定与酮替芬对过敏性结膜炎治疗效果的影响。
系统检索了PubMed、Embase、Web of Science、EBSCO和Cochrane图书馆数据库,纳入评估奥洛他定与酮替芬对过敏性结膜炎患者疗效影响的随机对照试验(RCT)。荟萃分析纳入了7项RCT。
总体而言,与酮替芬干预过敏性结膜炎相比,奥洛他定干预导致的结膜充血明显更少(平均差值(MD)=-0.77;95%置信区间(CI)=-1.24至-0.30;P=0.001),但对瘙痒、流泪或乳头增生无显著影响。
这些结果表明,奥洛他定在缓解过敏性结膜炎症状方面可能比酮替芬更有效。